This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of faster-acting insulin aspart (FIAsp) after different injection regions and routes of administration in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
Novo Nordisk Investigational Site
Neuss, Germany
Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration)
Time frame: From 0 to 12 hours
Area under the serum insulin aspart concentration-time curve (only for intramuscular administration)
Time frame: From 0 to 12 hours
Maximum observed serum insulin aspart concentration (only for subcutaneous and intramuscular administration)
Time frame: From 0 to 12 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.